Radius selected RAD140 from a series of promising selective androgen receptor modulators (SARM) after it demonstrated exceptional selectivity for anabolic activity in well-validated in vivo models.
Radius expects to complete formal toxicology studies that will allow the company to commence human clinical trials for RAD140 in the first half of 2009.
Richard Lyttle, president and CEO of Radius, said: “The selection of RAD140 for pre-IND development is a significant milestone for Radius as it represents the first novel proprietary compound to emerge from the company’s internal discovery program.”